2. Academic Validation
  3. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1

Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1

  • Biochem J. 2012 May 15;444(1):79-88. doi: 10.1042/BJ20111929.
Mark E Schnute 1,  Matthew D McReynolds,  Tom Kasten,  Matthew Yates,  Gina Jerome,  John W Rains,  Troii Hall,  Jill Chrencik,  Michelle Kraus,  Ciaran N Cronin,  Matthew Saabye,  Maureen K Highkin,  Richard Broadus,  Shinji Ogawa,  Kristin Cukyne,  Laura E Zawadzke,  Vincent Peterkin,  Kaliapan Iyanar,  Jeffrey A Scholten,  Jay Wendling,  Hideji Fujiwara,  Olga Nemirovskiy,  Arthur J Wittwer,  Marek M Nagiec
Affiliations

Affiliation

  • 1 Pfizer Global Research and Development, St. Louis Laboratories, Chesterfield, MO 63017, USA.
PMID: 22397330 DOI: 10.1042/BJ20111929
Abstract

SphK (sphingosine kinase) is the major source of the bioactive lipid and GPCR (G-protein-coupled receptor) agonist S1P (sphingosine 1-phosphate). S1P promotes cell growth, survival and migration, and is a key regulator of lymphocyte trafficking. Inhibition of S1P signalling has been proposed as a strategy for treatment of inflammatory diseases and Cancer. In the present paper we describe the discovery and characterization of PF-543, a novel cell-permeant inhibitor of SphK1. PF-543 inhibits SphK1 with a K(i) of 3.6 nM, is sphingosine-competitive and is more than 100-fold selective for SphK1 over the SphK2 isoform. In 1483 head and neck carcinoma cells, which are characterized by high levels of SphK1 expression and an unusually high rate of S1P production, PF-543 decreased the level of endogenous S1P 10-fold with a proportional increase in the level of sphingosine. In contrast with past reports that show that the growth of many Cancer cell lines is SphK1-dependent, specific inhibition of SphK1 had no effect on the proliferation and survival of 1483 cells, despite a dramatic change in the cellular S1P/sphingosine ratio. PF-543 was effective as a potent inhibitor of S1P formation in whole blood, indicating that the SphK1 isoform of sphingosine kinase is the major source of S1P in human blood. PF-543 is the most potent inhibitor of SphK1 described to date and it will be useful for dissecting specific roles of SphK1-driven S1P signalling.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z